Intravenous nizatidine kinetics and acid suppression

John Callaghan, Richard F. Bergstrom, Boyd D. Obermeyer, Edgar P. King, Walter W. Offen

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The effectiveness of intravenous nizatidine in suppressing gastric acid secretion was evaluated by different methods of inducing secretion in two single-blind studies. In study 1, seven subjects were given single, 20-min intravenous infusions of nizatidine (6.25, 25, 75, 150, or 250 mg) before modified sham feeding (MSF). Gastric acid suppression after nizatidine was contrasted with that after placebo and MSF. All doses of nizatidine reduced secretion; the 150- and 250-mg doses of nizatidine suppressed secretion for at least 2.5 hr. In study 2, eight subjects received one 5-min intravenous infusion of placebo, cimetidine (300 mg), or nizatidine (25, 50, 100, or 250 mg) weekly for 6 wk. Secretion was induced by infusing pentagastrin (2 μg/kg/hr) 45 min before the study drug was dosed and for 3.5 hr thereafter. Again, all doses of nizatidine reduced gastric acid, chiefly by decreasing volume. Nizatidine induced a clear dose-response effect; nizatidine (100 mg) and cimetidine (300 mg) had approximately equal suppressive effects. Nizatidine (100 mg) and cimetidine (300 mg) reduced acid output by 62% and 63% and reduced volume of secretion by 48% and 51% over the 3.5-hr period. Gastric acid suppression and plasma nizatidine concentrations were directly related. Nizatidine kinetics were linear and proportional to dose. The t 1 2 was 1.3 hr (range 0.7 to 2.1 hr), the volume of distribution was 1.2 ± 0.5 l/kg, and clearance was 0.6 ± 0.2 l/kg/hr. Laboratory abnormalities and side effects were minor in both studies.

Original languageEnglish (US)
Pages (from-to)162-165
Number of pages4
JournalClinical Pharmacology and Therapeutics
Volume37
Issue number2
StatePublished - Feb 1985

Fingerprint

Nizatidine
Acids
Gastric Acid
Cimetidine
Intravenous Infusions
Placebos
Single-Blind Method
Pentagastrin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Callaghan, J., Bergstrom, R. F., Obermeyer, B. D., King, E. P., & Offen, W. W. (1985). Intravenous nizatidine kinetics and acid suppression. Clinical Pharmacology and Therapeutics, 37(2), 162-165.

Intravenous nizatidine kinetics and acid suppression. / Callaghan, John; Bergstrom, Richard F.; Obermeyer, Boyd D.; King, Edgar P.; Offen, Walter W.

In: Clinical Pharmacology and Therapeutics, Vol. 37, No. 2, 02.1985, p. 162-165.

Research output: Contribution to journalArticle

Callaghan, J, Bergstrom, RF, Obermeyer, BD, King, EP & Offen, WW 1985, 'Intravenous nizatidine kinetics and acid suppression', Clinical Pharmacology and Therapeutics, vol. 37, no. 2, pp. 162-165.
Callaghan J, Bergstrom RF, Obermeyer BD, King EP, Offen WW. Intravenous nizatidine kinetics and acid suppression. Clinical Pharmacology and Therapeutics. 1985 Feb;37(2):162-165.
Callaghan, John ; Bergstrom, Richard F. ; Obermeyer, Boyd D. ; King, Edgar P. ; Offen, Walter W. / Intravenous nizatidine kinetics and acid suppression. In: Clinical Pharmacology and Therapeutics. 1985 ; Vol. 37, No. 2. pp. 162-165.
@article{ff97509367984a0eb4c852857610bd4b,
title = "Intravenous nizatidine kinetics and acid suppression",
abstract = "The effectiveness of intravenous nizatidine in suppressing gastric acid secretion was evaluated by different methods of inducing secretion in two single-blind studies. In study 1, seven subjects were given single, 20-min intravenous infusions of nizatidine (6.25, 25, 75, 150, or 250 mg) before modified sham feeding (MSF). Gastric acid suppression after nizatidine was contrasted with that after placebo and MSF. All doses of nizatidine reduced secretion; the 150- and 250-mg doses of nizatidine suppressed secretion for at least 2.5 hr. In study 2, eight subjects received one 5-min intravenous infusion of placebo, cimetidine (300 mg), or nizatidine (25, 50, 100, or 250 mg) weekly for 6 wk. Secretion was induced by infusing pentagastrin (2 μg/kg/hr) 45 min before the study drug was dosed and for 3.5 hr thereafter. Again, all doses of nizatidine reduced gastric acid, chiefly by decreasing volume. Nizatidine induced a clear dose-response effect; nizatidine (100 mg) and cimetidine (300 mg) had approximately equal suppressive effects. Nizatidine (100 mg) and cimetidine (300 mg) reduced acid output by 62{\%} and 63{\%} and reduced volume of secretion by 48{\%} and 51{\%} over the 3.5-hr period. Gastric acid suppression and plasma nizatidine concentrations were directly related. Nizatidine kinetics were linear and proportional to dose. The t 1 2 was 1.3 hr (range 0.7 to 2.1 hr), the volume of distribution was 1.2 ± 0.5 l/kg, and clearance was 0.6 ± 0.2 l/kg/hr. Laboratory abnormalities and side effects were minor in both studies.",
author = "John Callaghan and Bergstrom, {Richard F.} and Obermeyer, {Boyd D.} and King, {Edgar P.} and Offen, {Walter W.}",
year = "1985",
month = "2",
language = "English (US)",
volume = "37",
pages = "162--165",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Intravenous nizatidine kinetics and acid suppression

AU - Callaghan, John

AU - Bergstrom, Richard F.

AU - Obermeyer, Boyd D.

AU - King, Edgar P.

AU - Offen, Walter W.

PY - 1985/2

Y1 - 1985/2

N2 - The effectiveness of intravenous nizatidine in suppressing gastric acid secretion was evaluated by different methods of inducing secretion in two single-blind studies. In study 1, seven subjects were given single, 20-min intravenous infusions of nizatidine (6.25, 25, 75, 150, or 250 mg) before modified sham feeding (MSF). Gastric acid suppression after nizatidine was contrasted with that after placebo and MSF. All doses of nizatidine reduced secretion; the 150- and 250-mg doses of nizatidine suppressed secretion for at least 2.5 hr. In study 2, eight subjects received one 5-min intravenous infusion of placebo, cimetidine (300 mg), or nizatidine (25, 50, 100, or 250 mg) weekly for 6 wk. Secretion was induced by infusing pentagastrin (2 μg/kg/hr) 45 min before the study drug was dosed and for 3.5 hr thereafter. Again, all doses of nizatidine reduced gastric acid, chiefly by decreasing volume. Nizatidine induced a clear dose-response effect; nizatidine (100 mg) and cimetidine (300 mg) had approximately equal suppressive effects. Nizatidine (100 mg) and cimetidine (300 mg) reduced acid output by 62% and 63% and reduced volume of secretion by 48% and 51% over the 3.5-hr period. Gastric acid suppression and plasma nizatidine concentrations were directly related. Nizatidine kinetics were linear and proportional to dose. The t 1 2 was 1.3 hr (range 0.7 to 2.1 hr), the volume of distribution was 1.2 ± 0.5 l/kg, and clearance was 0.6 ± 0.2 l/kg/hr. Laboratory abnormalities and side effects were minor in both studies.

AB - The effectiveness of intravenous nizatidine in suppressing gastric acid secretion was evaluated by different methods of inducing secretion in two single-blind studies. In study 1, seven subjects were given single, 20-min intravenous infusions of nizatidine (6.25, 25, 75, 150, or 250 mg) before modified sham feeding (MSF). Gastric acid suppression after nizatidine was contrasted with that after placebo and MSF. All doses of nizatidine reduced secretion; the 150- and 250-mg doses of nizatidine suppressed secretion for at least 2.5 hr. In study 2, eight subjects received one 5-min intravenous infusion of placebo, cimetidine (300 mg), or nizatidine (25, 50, 100, or 250 mg) weekly for 6 wk. Secretion was induced by infusing pentagastrin (2 μg/kg/hr) 45 min before the study drug was dosed and for 3.5 hr thereafter. Again, all doses of nizatidine reduced gastric acid, chiefly by decreasing volume. Nizatidine induced a clear dose-response effect; nizatidine (100 mg) and cimetidine (300 mg) had approximately equal suppressive effects. Nizatidine (100 mg) and cimetidine (300 mg) reduced acid output by 62% and 63% and reduced volume of secretion by 48% and 51% over the 3.5-hr period. Gastric acid suppression and plasma nizatidine concentrations were directly related. Nizatidine kinetics were linear and proportional to dose. The t 1 2 was 1.3 hr (range 0.7 to 2.1 hr), the volume of distribution was 1.2 ± 0.5 l/kg, and clearance was 0.6 ± 0.2 l/kg/hr. Laboratory abnormalities and side effects were minor in both studies.

UR - http://www.scopus.com/inward/record.url?scp=0021843731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021843731&partnerID=8YFLogxK

M3 - Article

VL - 37

SP - 162

EP - 165

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -